Researchers Find Link Between Vitamin D and Asbestosis
This study was not designed to explain whether supplementing with vitamin D will protect against asbestosis. This new research also does not examine if taking vitamin D will slow down the progression of existing ILD. Still, there are a lot of good reasons to pay attention to the sunshine vitamin. Regardless of whether a person has been exposed to asbestos, no one should ignore very low vitamin D levels. People already diagnosed with an asbestos-related cancer, may benefit from a quick check of vitamin D levels. According to the medical literature, up to 80 percent of people with cancer may be vitamin D deficient. People ca...
Source: Asbestos and Mesothelioma News - July 16, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Vitamin D Deficiency Could Be Lung Disease Risk
MONDAY, June 25, 2018 -- Low levels of vitamin D are associated with an increased risk of a disease that causes lung inflammation and scarring, researchers say. About 200,000 cases of interstitial lung disease (ILD) are diagnosed each year in the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 25, 2018 Category: General Medicine Source Type: news

Low vitamin D linked to scarring lung disease
Lower than normal levels of vitamin D in the blood were linked to increased risk of early interstitial lung disease, according to an analysis of a new study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 19, 2018 Category: Consumer Health News Source Type: news

Low vitamin D levels associated with scarring lung disease
(Johns Hopkins Medicine) Reviewing medical information gathered on more than 6,000 adults over a 10-year period, Johns Hopkins researchers have found that lower than normal blood levels of vitamin D were linked to increased risk of early signs of interstitial lung disease (ILD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 19, 2018 Category: International Medicine & Public Health Source Type: news

Barriers to Timely Diagnosis of Interstitial Lung Disease Barriers to Timely Diagnosis of Interstitial Lung Disease
What are the barriers patients with interstitial lung diseases may face in obtaining a timely and accurate diagnosis?BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2018 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD). The FDA's Fast Track designation facilitates the development of new therapies that treat serious conditions and fulfill an unmet medical need in an effort to get treatments to those in need sooner. (Source: World Pharma News)
Source: World Pharma News - March 19, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Lung Disease Common in Late-Onset SLE (CME/CE)
(MedPage Today) -- Rates of interstitial lung disease more than doubled (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 6, 2018 Category: Primary Care Source Type: news

Medical News Today: What to know about interstitial lung disease
A look at interstitial lung disease, a group of diseases that make it difficult to get enough oxygen. Included is detail on types and complications. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 18, 2018 Category: Consumer Health News Tags: Pulmonary System Source Type: news

Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial
Bellerophon Therapeutics (NSDQ:BLPH) has enrolled the first patient in a Phase IIb study assessing its INOpulse device in patients with pulmonary hypertension due to interstitial lung disease. The company’s placebo-controlled study is slated to evaluate the safety and efficacy of pulsed, inhaled nitric oxide in patients with PH-ILD, including those with idiopathic pulmonary fibrosis, Bellerophon reported. Get the full story at out sister site, Drug Delivery Business News. The post Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 4, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Bellerophon Therapeutics Source Type: news

Exercise Training in Interstitial Lung Disease Exercise Training in Interstitial Lung Disease
Pulmonary rehabilitation programs including exercise training may be an effective intervention in stable patients with interstitial lung disease.Thorax (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Warning of too few specialist nurses for incurable lung disease
A lack of access to specialist nurses is an important factor contributing to a crisis in care for patients with interstitial lung disease (ILD), according to a charity report. (Source: Nursing Times)
Source: Nursing Times - September 18, 2017 Category: Nursing Source Type: news

Interstitial Pneumonitis (Interstitial Lung Disease)
Title: Interstitial Pneumonitis (Interstitial Lung Disease)Category: Diseases and ConditionsCreated: 11/10/2014 12:00:00 AMLast Editorial Review: 8/8/2017 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - August 8, 2017 Category: Respiratory Medicine Source Type: news

Occupational Exposures Linked to Interstitial Lung Disease
Job exposure matrix score increase in vapors, gas, dust, fumes exposure ups high attenuation areas (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - August 7, 2017 Category: Respiratory Medicine Tags: Pulmonology, Journal, Source Type: news

FDA accepts Bellerophon ’s Phase IIb design for INOpulse in PH-ILD
The US Food and Drug Administration (FDA) has accepted Bellerophon Therapeutics ’ study design for the Phase IIb clinical trial of INOpulse in patients with Interstitial Lung Disease (ILD) associated pulmonary hypertension (PH). (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2017 Category: Pharmaceuticals Source Type: news

Interstitial Lung Disease Boosts Mortality in RA (CME/CE)
(MedPage Today) -- New study highlights need for early diagnosis, better treatments (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - June 27, 2017 Category: Respiratory Medicine Source Type: news

National Jewish Health and partner to establish respiratory institute in Philadelphia
Denver's National Jewish Health, which focuses on respiratory care, is teaming up with Philadelphia hospital system Jefferson Health to create the Jane and Leonard Korman Respiratory Institute in Philadelphia. The institute — expected to open this summer — is being created to define the best practices for treating and researching pulmonary diseases and related disorders. Such conditions include chronic obstructive pulmonary disease, asthma, interstitial lung disease, sarcoidosis, and infectious… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 26, 2017 Category: Pharmaceuticals Authors: John George Source Type: news

National Jewish Health and partner to establish respiratory institute in Philadelphia
Denver's National Jewish Health, which focuses on respiratory care, is teaming up with Philadelphia hospital system Jefferson Health to create the Jane and Leonard Korman Respiratory Institute in Philadelphia. The institute — expected to open this summer — is being created to define the best practices for treating and researching pulmonary diseases and related disorders. Such conditions include chronic obstructive pulmonary disease, asthma, interstitial lung disease, sarcoidosis, and infectious… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 26, 2017 Category: Biotechnology Authors: John George Source Type: news

Jefferson, Denver specialty hospital to establish respiratory institute in Philadelphia
Jefferson Health is teaming up with National Jewish Health, a 118-year-old specialty hospital in Denver that focuses on respiratory care, to create the Jane and Leonard Korman Respiratory Institute in Philadelphia. The institute — expected to open this summer — is being created to define the best practices for treating and researching pulmonary diseases and related disorders. Such conditions include chronic obstructive pulmonary disease, asthma, interstitial lung disease, sarcoidosis, and infectious… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 26, 2017 Category: Pharmaceuticals Authors: John George Source Type: news

Jefferson, Denver specialty hospital to establish respiratory institute in Philadelphia
Jefferson Health is teaming up with National Jewish Health, a 118-year-old specialty hospital in Denver that focuses on respiratory care, to create the Jane and Leonard Korman Respiratory Institute in Philadelphia. The institute — expected to open this summer — is being created to define the best practices for treating and researching pulmonary diseases and related disorders. Such conditions include chronic obstructive pulmonary disease, asthma, interstitial lung disease, sarcoidosis, and infectious… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 26, 2017 Category: Biotechnology Authors: John George Source Type: news

Boehringer begins enrolment in Phase III trial of nintedanib for fibrosing lung diseases
US-based Boehringer Ingelheim Pharmaceuticals has begun patient enrolment in the Phase III progressive fibrosing interstitial lung disease (PF-ILD) clinical trial of nintedanib to treat various progressive fibrosing lung diseases, excluding idiopathi … (Source: Drug Development Technology)
Source: Drug Development Technology - April 20, 2017 Category: Pharmaceuticals Source Type: news

Clinical Course of Anti-EJ Antibody-Related Lung Disease Clinical Course of Anti-EJ Antibody-Related Lung Disease
A new study describes the clinical features of patients with anti-glycyl-tRNA synthetase antibody-positive interstitial lung disease.BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 24, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 8, 2016 Category: Research Source Type: news

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 7, 2016 Category: Research Source Type: news

Consultation on specialised services clinical commissioning policies
NHS England has launched a 30 day public consultation on two proposed new clinical commissioning policies for specialised services – specifically Rituximab for the treatment of primary Sjogren’s syndrome in adults, and Rituximab in connective tissue disease associated interstitial lung disease in adults. (Source: NHS Networks)
Source: NHS Networks - May 2, 2016 Category: UK Health Source Type: news

Anti-fibrotic peptide shows early promise against interstitial lung disease
The M10 peptide reduces collagen production and reverses fibrotic damage due to systemic sclerosis (SSc)-related interstitial lung disease (ILD), preclinical findings suggests. ILD is one of the deadliest complications of SSc, a chronic autoimmune disease characterized by vasculopathy, autoimmunity, and excessive collagen production and deposition. Lung fibrosis carries a high risk of morbidity/mortality in SSc patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 13, 2016 Category: Science Source Type: news

Anti-fibrotic peptide shows early promise against interstitial lung disease
(Medical University of South Carolina) Investigators at the Medical University of South Carolina report preclinical findings showing that the M10 peptide reduces collagen production and reverses fibrotic damage due to systemic sclerosis (SSc)-related interstitial lung disease (ILD) in the April 2016 issue of Translational Research. ILD is one of the deadliest complications of SSc, a chronic autoimmune disease characterized by vasculopathy, autoimmunity, and excessive collagen production and deposition. Lung fibrosis carries a high risk of morbidity/mortality in SSc patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 13, 2016 Category: Global & Universal Source Type: news

Interstitial Lung Disease Tied to All-Cause Death Risk (CME/CE)
(MedPage Today) -- Specific set of lung abnormalities may be especially problematic for older patients (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - February 17, 2016 Category: Geriatrics Source Type: news

RheumNow: Interstitial Lung Disease Not Increased With Biologics
(MedPage Today) -- New study explores risk of ILD in RA patients on biologics (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 28, 2015 Category: Primary Care Source Type: news

Promising treatment for scleroderma-related interstitial lung disease
Mycophenolate mofitil is as effective as cyclophosphamide in treating interstitial lung disease in people with scleroderma, according to new research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 8, 2015 Category: Science Source Type: news

VIDEO: MMF equals cyclophosphamide’s efficacy in sclerodermal lung disease
MONTREAL – The immunosuppressant mycophenolate mofetil worked as effectively as cyclophosphamide for treating scleroderma-related interstitial lung disease while being better tolerated and causing fewer adverse effects in a multicenter, head-to-head comparison with 142 randomized patients. “The... (Source: Skin and Allergy News)
Source: Skin and Allergy News - November 3, 2015 Category: Dermatology Source Type: news

Fewer Mycophenolate Adverse Events in Scleroderma Lung StudyFewer Mycophenolate Adverse Events in Scleroderma Lung Study
Results from the first clinical trial comparing mycophenolate with cyclophosphamide suggest that treatment options for scleroderma-related interstitial lung disease are expanding. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 2, 2015 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

RA: Lung Disease Risk Tracks Biomarkers (CME/CE)
(MedPage Today) -- Standard RA biomarkers appear to raise risk of interstitial lung disease (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 24, 2015 Category: Geriatrics Source Type: news

Baseline CT scans predict lung fibrosis in SSc
Patients with newly diagnosed systemic sclerosis should have a high-resolution lung CT and pulmonary function tests, because when assessed together, their findings identify patients at high risk of interstitial lung disease, researchers say. In a study of 305 patients with systemic sclerosis... (Source: Skin and Allergy News)
Source: Skin and Allergy News - May 2, 2015 Category: Dermatology Tags: CME-candidate IMN News RHEUM News RHEUM Lupus/Connective Tissue Diseases CHEST Pulmonary Medicine CHEST Clinical News CHEST News FPN News Source Type: news

Interstitial Lung Disease
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 22, 2015 Category: Journals (General) Source Type: news

Interstitial Lung Disease in Systemic SclerosisInterstitial Lung Disease in Systemic Sclerosis
How often should systemic sclerosis patients be screened for interstitial lung disease? Annals of the Rheumatic Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 3, 2015 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Interstitial lung disease is significant risk factor for lung inflammation
Pretreatment interstitial lung disease is a significant risk factor for developing symptomatic and severe radiation pneumonitis in stage I non-small cell lung cancer patients treated with stereotactic body radiation therapy alone, researchers say. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 10, 2014 Category: Science Source Type: news

Interstitial Lung Disease (Interstitial Pneumonitis)
Title: Interstitial Lung Disease (Interstitial Pneumonitis)Category: Diseases and ConditionsCreated: 11/10/2014 12:00:00 AMLast Editorial Review: 11/10/2014 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - November 10, 2014 Category: Respiratory Medicine Source Type: news

Interstitial Pneumonitis (Interstitial Lung Disease)
Title: Interstitial Pneumonitis (Interstitial Lung Disease)Category: Diseases and ConditionsCreated: 11/10/2014 12:00:00 AMLast Editorial Review: 11/10/2014 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - November 10, 2014 Category: Respiratory Medicine Source Type: news

Interstitial lung disease is a significant risk factor for lung inflammation
(International Association for the Study of Lung Cancer) Pretreatment interstitial lung disease is a significant risk factor for developing symptomatic and severe radiation pneumonitis in stage I non-small cell lung cancer patients treated with stereotactic body radiation therapy alone. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 10, 2014 Category: Global & Universal Source Type: news

Isolation of . from the Blood of a Patient with Interstitial Lung Disease
The genus Laceyella within the family Bacillaceae was proposed by Yoon et al. (1) in 2005 and was placed in the family Thermoactinomycetaceae by Matsuo et al. (2) in 2006. Members of the genus Laceyella were initially considered to belong in the genus Thermoactinomyces (also known as actinomycetes). When Yoon and colleagues (1) first proposed the genus Laceyella, only two species were known: Laceyella sacchari and Laceyella putidus, which were previously named Thermoactinomyces sacchari (Thermoactinomyces thalpophilus) and Thermoactinomyces putidus, respectively (1,3). (Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - August 23, 2014 Category: Microbiology Authors: Shobha Parajuli, Raghava Potula, David Ciccolella, Allan L. Truant Tags: Case Report Source Type: news

RheumShorts: Fibromyalgia, Scleroderma, Spondylitis (CME/CE)
(MedPage Today) -- News in rheumatology this week included water therapy for fibromyalgia, Gleevec for the often-lethal interstitial lung disease in scleroderma, and a temporary setback for apremilast in ankylosing spondylitis. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 10, 2014 Category: Primary Care Source Type: news

Lung Disease in RA Common, Lethal
(MedPage Today) -- Patients with rheumatoid arthritis-associated interstitial lung disease tend to have a distinct clinical phenotype that includes older age, respiratory symptoms, and worse RA overall -- and are at substantial risk for early mortality, researchers reported. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 2, 2014 Category: Primary Care Source Type: news

Rituximab May Help in RA Lung Disease
LIVERPOOL (MedPage Today) -- Patients with rheumatoid arthritis who have interstitial lung disease (ILD) appeared to have a survival advantage if treated with rituximab rather than with a tumor necrosis factor (TNF) inhibitor, a researcher said here. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 30, 2014 Category: Geriatrics Source Type: news

InterMune® announces support for first ever European Patient Charter on idiopathic pulmonary fibrosis (IPF)
To mark international Rare Disease Day, InterMune has announced its support for the development of a European Patient Charter for people with idiopathic pulmonary fibrosis (IPF). IPF is an irreversible, progressive and ultimately fatal fibrotic interstitial lung disease,. IPF has a projected survival rate of only 20-40% after five years1, 2 making it more rapidly lethal than many cancers3, 4. The disease causes scarring of the lungs, irreversibly destroying normal lung architecture and hindering a person's ability to breathe. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 3, 2014 Category: Consumer Health News Tags: Respiratory / Asthma Source Type: news

Toxic inhalational injury-associated interstitial lung disease in children - Lee E, Seo JH, Kim HY, Yu J, Jhang WK, Park SJ, Kwon JW, Kim BJ, Do KH, Cho YA, Kim SA, Jang SJ, Hong SJ.
Interstitial lung disease in children (chILD) is a group of disorders characterized by lung inflammation and interstitial fibrosis. In the past recent years, we noted an outbreak of child in Korea, which is possibly associated with inhalation toxicity. Her... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - February 22, 2014 Category: Global & Universal Tags: Age: Infants and Children Source Type: news

Toxic Spill in West Virginia: Tox on the Web
Chemical Leak in West Virginia: On her Wired Science blog Elemental, @deborahblum tries to track down information about 4-methylcyclohexane methanol (MCHM), a “detergent” (foaming agent) used for washing coal that leaked from a storage tank into West Virginia’s Elk River on Thursday. Not much is known about the toxicology and risk of MCHM, except that it is an irritant. In the meantime, hundreds of thousands of West Virginia residents have been advised to stop drinking and bathing in tap water. Blum makes the important point that, although at this point MCHM does not seem to be overwhelmingly to...
Source: The Poison Review - January 12, 2014 Category: Toxicology Authors: Leon Tags: Medical amiodarone carbon monoxide toxicity child abuse dolphins elk river hyperbaric oxygen methylcyclohexane puffer fish toxic leak west virginia Source Type: news

Interstitial Lung Disease
Title: Interstitial Lung DiseaseCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 12/12/2013 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - December 12, 2013 Category: Respiratory Medicine Source Type: news

Children's Interstitial Lung Diseases in Early Infancy
This article describes the lesser-known conditions that have the potential to cause significant pulmonary disease in infancy. (Source: NeoReviews recent issues)
Source: NeoReviews recent issues - November 1, 2013 Category: Pediatrics Authors: Arzuaga, B. H., Mathai, T., Khan, O. Tags: Articles Source Type: news

Acute Exacerbations in Patients With Idiopathic Pulmonary FibrosisAcute Exacerbations in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is a chronic, fibrosing interstitial lung disease that primarily affects older adults. Find out how to handle the heat of exacerbation. Respiratory Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 4, 2013 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news